Precision Hodgkin's and Non-Hodgkin's Lymphoma Treatment Options Are One Call Away
Call Now
Early, Late-Stage, and Metastatic Hodgkin’s and Non-Hodgkin’s
Lymphoma Treatment
Personalized Lymphoma Treatment Options Designed to
Precision-Target Your Cancer
Lymphoma is a complicated cancer of the immune system cells, which may be difficult to diagnose and treat accurately
due
to its multiple types and subtypes, but our advanced diagnostics and precision-targeted immunotherapies prove
beneficial
in overcoming these challenges.
At Envita Medical Centers, a Center of Excellence for Integrative Precision Oncology, we have been successfully
treating
Hodgkin’s and Non-Hodgkin’s Lymphoma patients who were left with limited options in well-renowned cancer treatment
facilities in America.
Our proprietary new treatments, including personalized immunotherapies, GTFC, and CIPI™, go beyond the scope of
standard
high-dose chemotherapy, radiation therapy, untargeted immunotherapy, and bone marrow transplant or stem cell
transplant,
to help patients progress towards a holistic recovery. In our clinical experience of over 25 years, utilizing a
powerful
combination of the latest in conventional and natural medicines offers the potentially best treatment suitable for
each
patient’s individual lymphoma.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
Lymphomas can affect any organ or part of the body, including lymph nodes, spleen, bone marrow, or intestines, as it
is
a form of blood cancer impacting the lymphocytes, which are a type of white blood cells. Though lymphomas are a type
of
blood cancer, they are particularly different from leukemia, which is another type of blood cancer.
This article covers important information about Lymphoma treatment, including:
The Envita Edge in Treating Hodgkin’s and Non-Hodgkin’s Lymphomas
Our pioneering research in the field of Immunotherapy in Cancer Treatment gives
our physician team an advantage when
treating this cancer of the lymphatic system. We custom-build
patient-specific treatments to bolster the immune system’s ability to attack cancer cells, while reducing chances of
side effects associated with untargeted, standardized cancer treatment.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
Lymphomas are divided into various types and sub types such as Hodgkin’s Lymphoma, Non-Hodgkin’s Lymphoma, Burkitt
Lymphoma, or Diffuse Large B Cell Lymphoma, depending on the type of the lymphocyte where the cancer originates. Other
factors like, whether the cancer is aggressive (fast growing) or indolent (slow growing), organs or parts of the body
affected by the cancer, and presence of certain types of abnormal cells, also help in accurate diagnosis of specific
sub
types. We bring the latest in cancer research from around the world to not only strike at the varied types and
subtypes
of Lymphomas, but our expert care team, including medical oncologists, radiation oncologists, and researchers,
personalize these treatments to enhance patient response.
Envita Medical Centers Medical Team
Physicians with MD, MD(h), and NMD medical
licenses, including certified oncologists, and certified interventional radiologists,
striving to provide the latest cancer innovations
22
Pharmacists specializing in integrative agents
7
Nurses trained in precision treatment delivery
40+
Overcoming Challenges of Standard Treatments and Clinical Trials
The lack of personalization in standardized oncology treatments and clinical trials explains why they are not
equally
effective for every patient with the same stage and type of cancer, leading to chemotherapeutic drug
resistance and
further metastatic spread.
Cancer Cell Pumping Out Untargeted Chemotherapy Drugs
Recent medical studies highlight the need for
a better understanding of
the
molecular mechanisms that underlie inherent or acquired drug resistance to prevent its impact on Non-Hodgkin Lymphoma
treatment. Envita’s personalized precision oncology treatments are designed on a detailed understanding of the
Lymphoma’s molecular mechanisms, but access to precision oncology is restricted to a limited few in other major cancer
centers of the country.
At Envita, Every Patient Gets the Benefit of Personalized Precision
Oncology Treatments Right From the Beginning of
Care!
We break away from the one-size-fits-all standard regimens, dictated by the National Cancer Institute’s NCCN
(National
Comprehensive Cancer Network) guidelines, to offer the benefits of personalized precision oncology to all our patients
right from the beginning of their care. The earlier you get access to precision, the better are your chances of
countering the risks of chemotherapeutic drug resistance and metastasis.
The NCCN guidelines, followed by all major cancer centers, do not allow precision oncology as an initial treatment to
every patient, instead it is used as a follow-up to initial treatments if the cancer relapses. Generally, the disease
is
more resistant and complex to treat when it relapses, which explains why the delay in access to precision oncology may
be catastrophic when dealing with life-threating conditions like lymphoma cancers.
To Reduce These Risks, We Utilize Our Advanced Precision Oncology
Algorithms Which Analyze Many More Parameters Than
Standard Oncology Precision Testing.
Envita Precision Algorithm vs. Standard Oncology Precision Testing
Envita Medical Centers
Standard Oncology Precision Testing
RNA Transcriptome Genes
Envita Medical Centers:20,000+
Standard Oncology:Unchecked
SNV/CNV Genes
Envita Medical Centers:452
Standard Oncology:309
Rearrangements/Fusion Genes
Envita Medical Centers:51
Standard Oncology:27
Microsatellite Instability (MSI)
Envita Medical Centers:Checked
Standard Oncology:Checked
Tumor Mutation Burden (TMB)
Envita Medical Centers:Checked
Standard Oncology:Checked
BRCA 1/2
Envita Medical Centers:Checked
Standard Oncology:Checked
Immunohistochemistry
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Chemosensitivity
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Concurrent Liquid Biopsy
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Exosomal miRNA Analysis
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Circulating Tumor Cells Enumeration
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Pharmacogenomics
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Individualized Therapy Recommendation
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Carcinogenic Exposure - Root Causes
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Inflammation Markers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Metabolic Target Drivers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
Analyzing all these parameters allows us to personalize care utilizing thousands of analytes, going beyond standard
oncology treatment options and even clinical trials. These large sample clinical trials are focused on testing the
efficacy of new treatments, which explains why participants should approach clinical trials
with caution as
responses may vary from patient to patient.
Envita’s Patient-Tailored New Treatments
Envita’s new treatments are designed on the N-of-1
clinical trial
approach, which is a single subject clinical trial, aimed at
precision-targeting all the factors responsible for the growth and spread of lymphoma cancers in each individual
patient. This simply means that your treatment plan is built only for you, as each individual patient has their own
treatment plan customized to them. This customized treatment approach goes beyond the standard one-size-fits-all
regimens of either watchful waiting for slow-growing tumors, or high dose chemotherapy, radiation, and other
treatments
for fast-growing tumors.
We believe the future of cancer treatment will be going in this direction someday but in the meantime Envita
continues
to go above-and-beyond for our patients. We develop a unique medical blueprint for each patient based on a four-step
process, to aid in optimizing quality of life, increasing longevity, and reducing toxicities.
Step 1
Genomic Identification for Precision Diagnosis
Envita’s in-depth genomic testing methods go beyond the traditional diagnostic methods of biopsies and imaging to not
only help in accurate analysis of the disease subtype, but to also attack the core cause of this complicated lymphoma
cancer.
In our clinical experience, at the root of most lymphomas are undiagnosed causative agents such as chronic infections
and chemical toxins, which are responsible for triggering the genetic mutations leading to lymphoma cancers.
Our published study on “Cancer and
Infectious Causes" indicate how different viruses like Epstein-Barr Virus (EBV) and other pathogens can trigger
lymphomas. To tackle these
unique set of cancer drivers in each individual patient and build a comprehensive lymphoma treatment plan, we dive
into
an exhaustive genomic analysis, which is much more
detailed than
standard testing.
A detailed investigation of all the genetic and environmental parameters helps in developing your true medical
blueprint, which is the empirical foundation to building your comprehensive cancer treatment protocol.
Step 2
Immuno Targeting to Enhance Treatment Options
At Envita, we utilize different levels of immunotherapies for all our lymphoma cancer patients, irrespective of their
stage or type of cancer. A weakened immune system may be considered one of the biggest risk
factors
for developing
Lymphomas,
which is why our personalized treatment protocols comprise various advanced immunotherapies, including biologic
therapies, which induce a patient’s immune system to identify and kill cancer cells in the body.
Our genetically targeted immunotherapies are designed to overcome the limitations of standard monoclonal antibodies,
cancer vaccines, and CAR (Chimeric Antigen Receptor) T cell therapies, allowing a larger number of patients to
potentially benefit from advanced immunotherapies. For example, as part of the CAR T-cell therapy, special proteins
are
added to the surface of a patient’s T cells, a type of white blood cells so they can find and kill your specific type
of
cancer cells, but only certain subsets of
cancer patients are
eligible for
this immunotherapy, as extending it beyond this group may trigger adverse consequences. However, at Envita, we try to
overcome this challenge by using a combination of immunotherapies and personalizing them as needed, to enhance
treatment
options for patients with even late-stage and complicated lymphoma cancers.
Ultra Analytes Liquid Biopsy
Ultra Analytes Liquid Biopsy is deployed to identify targeted immunotherapy options to help get your
immune system working properly again.
Learn more
about
Immunotherapy
To personalize treatments, we utilize Envita’s Ultra Analytes Liquid Biopsy which improves chemotherapy and
immunotherapy targeting, allowing patients to experience treatment benefits with minimal side effects. The
liquid
biopsy
is a simple blood test drawn to analyze the circulating tumor cells (CTCs), which break away from a growing
tumor and
spread the disease to different parts of the body. A detailed analysis of these CTCs enables our expert medical
team
to
proactively treat the disease and check metastases in both late and early-stage lymphoma cancers.
Step 3
Personalized Drug Design to Take Cancer Care to the Next Level
Our treatment options are not limited to the standard drugs available on the market for lymphomas, as we take
cancer
care to the next level by harnessing the potential of custom compounded adjuvants from our in-house pharmacy.
These adjuvants are based on
advanced research-based phytotherapeutics including plant extracts and herbs, which have proven to be
effective against
specific cancerous mutations.
FDA Approved Drugs
Optimized for your cancer mutations.
Repurposed Drugs
Off-label use of approved medications
Custom Compounded Adjuvants
Genetically typed for each patient.
Our personalized drug
design
also includes
FDA (Food
and Drug Administration) approved and repurposed drugs along with custom-compounded adjuvants to attack lymphomas from
all possible angles. We even adjust the dosage of FDA approved and repurposed drugs to suit each patient’s individual
rate of metabolism, which helps to maximize treatment benefits while reducing side effects.
Precision Deployment of New Treatments for a Holistic Recovery
These personalized drugs are precision deployed to directly strike at the cancerous cells with minimal impact to
adjoining healthy cells and tissues. Envita’s proprietary new treatments not only increase the bioavailability of our
customized anti-cancer medications, but also aim to reactivate the patient’s immune system to reduces chances of
potential recurrence or metastatic spread of lymphomas.
Following are some of our proprietary new treatments:
Genetically Targeted Fractionated Chemotherapy GTFC, is an exclusive treatment program developed by Envita Medical
Centers to offer a synergetic combination of genetically targeted, micro-dosed chemotherapies and adjuvant agents. It
is
delivered intravenously and is designed to hit more biomarkers than standard high-dose chemotherapies, leading to
potentially improved patient responses. Biomarkers are attributes of cancer cells containing specific chemotherapy and
immunotherapy targets.
Envita's GTFC™ vs. Standard Chemotherapy
Envita Medical Centers
Standard Chemotherapy
Helps to improve chemotherapy delivery to the tumor using a "Trojan Horse" delivery mechanism.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses genetic molecular profiling to understand all the facets of each patient's specific cancer.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses targeted treatment to enhance the mechanism of cancer kill.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses microdosed (fractionated) chemotherapies, reducing the chances of impacting healthy cells.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Minimizes toxicity to normal cells, lowering the chance of side-effects related to administration.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses patient-specific supportive immunotherapy to strengthen the immune system.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Aims to reduce multidrug resistance by administering 10 - 20% of the medication delivered in maximum dose
chemo.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Allows custom-compounded medications to be readministered in tandem to suit each patient's individual cancer
mutations.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
Chemotherapy agents are designed to work on differing mechanisms of action to attack cancer, such as slowing the
mutation of cancer, turning down the signaling of cancer cells, enhancing immune system response, and killing tumor
cells. Standard chemotherapy treatment options often utilize one or two of these mechanisms of action at a time, but
the
fractionated dosing in GTFC™ allows us to use multiple chemotherapies with differing mechanisms of action as part of a
single treatment protocol. We blitz cancer with an array of precision-targeted cancer agents, supportive integrative
approaches, and patient specific methods to potentially improve patient responses to care.
CIPI™ (Chemo Immuno Precision Injections)
CIPI™ is our proprietary minimally invasive surgical procedure for tumor chemoembolization, and it is especially
helpful
in tackling aggressive cancers like late-stage Hodgkin or Non-Hodgkin Lymphoma with metastases to
difficult-to-reach organs. Performed through interventional radiology, this procedure directly targets the tumor with
chemotherapies and immunotherapies, specifically tailored for each individual patient and their unique Lymphoma
expressions. These customized anti-cancer medications deactivate the tumors while creating an immune system response,
which trains the body to identify and kill cancer cells to check chances of future growth or spread of disease.
Envita's CIPI™ vs. Standard Surgery
Envita Medical Centers
Standard Surgery
Minimally invasive so it can be performed within 40-50 minutes, without the need for large surgical
incisions.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Can be performed multiple times, even at close intervals, because there is minimal risk of post-op
complications.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
No need for general anesthesia, reducing the health risks that can result from being put into a
medically induced coma to perform an invasive surgery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Faster recovery time as compared to traditional surgery, due to the minimally invasive administration.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Provides direct tumor targeting, which delivers patient-specific genomic agents into the tumor.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Causes a systemic immune response where the immune system is reactivated to find and attack other
metastatic cancer sites in the body.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Performed by highly trained medical professionals in an outpatient setting, so there is no need of
hospital stays for recovery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
Hodgkin’s Lymphoma: Usually originates in the B lymphocytes, are characterized by the presence of the
abnormal Reed-Sternberg cells, and are
rarer than Non Hodgkin Lymphoma.
Non-Hodgkin’s Lymphoma (NHL): Can originate either in the B lymphocytes (B cells), T lymphocytes (T
cells), or Natural Killer lymphocytes (NK cells),
but B-cell Non-Hodgkin Lymphomas are more common. There are over 60 different subtypes of NHL, following are
some of the common sub types of Non-Hodgkin’s Lymphoma:
Diffuse Large B Cell Lymphoma: This is the most common form of aggressive NHL, and it can involve
other
organs apart
from the lymph nodes. There are variations even within this subset of NHL.
Follicular Lymphoma: This is the second most common form of NHL, which can be indolent or
aggressive. It
usually begins
in the B cells of the lymph nodes and can spread to different parts of the body.
T cell Lymphoma: This sub type is further divided into numerous other disease forms. Certain forms
of this
disease may
originate in the skin or bones.
Burkitt lymphoma: This is a rare but aggressive type of B cell Lymphoma, with different variations
to it.
Mantle cell lymphoma: It is a B cell NHL, usually involving the lymph nodes, spleen, bone marrow,
and the
gastrointestinal system.
Symptoms of Lymphomas
Unexplained weight loss
Night sweats
Swollen lymph nodes in any part of the body
Persistent fever
Chronic fatigue
Itchy or irritable skin
Hear from Our Hodgkin’s and Non-Hodgkin’s Lymphoma Survivors
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
Our expert medical team comprising oncologists, interventional radiologists, researchers, and pharmacists,
collaborate
to attack the various types of Hodgkin’s and Non-Hodgkin’s Lymphomas from all possible angles. They have undergone
over
1,500 hours of training to adapt to our unique personalized precision oncology approach. We combine the latest in
research-based naturopathic and conventional treatment options from around the world, not just the United States. If
you
or a loved one is suffering from any form of Lymphoma cancers, please contact us at: 866-830-4576. May God bless you
on
your journey to healing.
Our team is ready to help you get your life back! Please enter your contact information and a Patient Care
Expert will contact you shortly. If you would rather speak now, please give us a call at 1-866-830-4576.
